Identifying the Subcutaneous Osteoporosis Drug

The question asks for a drug used in the treatment of osteoporosis that is administered via the subcutaneous route. The correct answer is Denosumab.

Analysis of Each Option

• Zoledronic acid: A potent nitrogen-containing bisphosphonate used for osteoporosis, but it is given as an intravenous (IV) infusion, typically once yearly. It is not a subcutaneous preparation, so this option is incorrect.
• Alendronate: An oral bisphosphonate taken as a weekly or daily tablet. It is not injectable, so it does not satisfy the subcutaneous criterion.
• Denosumab: A fully human monoclonal antibody (IgG2) directed against RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). By binding RANKL, it prevents RANKL from activating its receptor RANK on the surface of osteoclasts and their precursors, thereby inhibiting osteoclast formation, function, and survival. This reduces bone resorption and increases bone mineral density. Denosumab is given as a subcutaneous injection once every 6 months and is approved for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. This matches the question exactly.
• Raloxifene: A selective estrogen receptor modulator (SERM) used in postmenopausal osteoporosis, but it is administered orally as a daily tablet, not by injection.

Conclusion

Among the listed drugs, only Denosumab is formulated for subcutaneous administration while being indicated for osteoporosis treatment. Zoledronic acid (IV), Alendronate (oral), and Raloxifene (oral) are all administered by non-subcutaneous routes, making them incorrect for this question. Therefore, the correct answer is Denosumab.